CEE Webinar Series

1. The Sequel: CNS Opportunistic Infections in People with HIV in the US

September 25th, 2025 | 12:00 PM - 1:00 PM

Presented by:
Deborah Kahal, MD, MPH
Clinical Associate Professor, Division of Internal Medicine
Thomas Jefferson University Hospital, Department of Medicine
Medical Consultant, Delaware County Health Department

Learning Objectives: 

1. Describe trends in the incidence of opportunistic infections in people with HIV, including cryptosporidiosis, toxoplasmosis, and tuberculosis.

2. Identify central nervous system (CNS) clinical manifestations of specific opportunistic infections in the US among people with HIV and describe treatment options.

3. Discuss recommendations for antiretroviral therapy and treatment of specific opportunistic infections concurrently.

Activity:
Review clinical case studies to practice identifying select opportunistic infections, clinical care, and ongoing approaches for medical management of patients with HIV.

2. Altering Antiretroviral Therapy: Rationale and Approaches

October 2025

Presented by:
Nicole Bryan, MD, PhD
Associate Professor, Infectious Diseases Fellowship Program Director 
West Virginia University (WVU), Department of Infectious Disease 
WVU Regional Director, MidAtlantic AIDS Education and Training Center 

Learning Objectives: 

1. Identify the clinical scenarios that may warrant a switch or simplification of antiretroviral therapy, including treatment failure, side effects, and patient preference.
   

2. Discuss characteristics to assess in patients with HIV, including comorbidities, adherence, viral load history, and resistance when considering a change in antiretroviral therapy.
   

3. Explore techniques for involving patients in the decision-making process and fostering adherence to new HIV treatment regimens.

Activity:
In small groups, discuss potential approaches or next steps for common patient concerns regarding antiretroviral therapy changes, health maintenance considerations, and strategies for effective patient education to promote retention in HIV care.

3. Navigating Cancer Risk in People with HIV: A Whole-Person Approach to Screening and Treatment

November 2025

Presenter TBA

Learning Objectives: 

1. Review the clinical signs and symptoms of AIDS-defining cancers, as well as the appropriate screening methods for individuals with HIV.
   

2. Describe physiological mechanisms that drive cancer risk for people with HIV.
   

3. Discuss the clinical signs and symptoms of non-AIDS-defining cancers and the corresponding screening methods for people with HIV.
   

4. Explore clinical considerations for cancer treatment in people with HIV.

Activity:
In this interactive training activity, participants will work collaboratively in small groups to analyze clinical case studies focused on patients with HIV. Together, they will identify potential cancer risks, explore appropriate screening methods, and consider treatment strategies while applying a whole-person approach. 

4. HIV and Aging Innovative Models of Care: Managing Polypharmacy, Frailty, and Neurocognitive Decline in Clinical Practice

December 2025

Presenter TBA

Learning Objectives: 

1. Describe the unique clinical challenges associated with aging in people with HIV (PWH), including accelerated aging, multimorbidity, and increased vulnerability to geriatric syndromes, including criteria measured via validated screening tools.
   

2. Identify common patterns of polypharmacy in older PWH and evaluate strategies to deprescribe or adjust medications to minimize adverse drug interactions and optimize ART adherence.
   

3. Discuss approaches to integrate HIV and aging considerations into routine primary care workflows, including emerging innovative models of care.

Activity:
Using case studies, assess for frailty and functional decline in aging PWH using validated screening tools (e.g., FRAIL scale, gait speed, IADL assessments), and interpret results to inform care planning.

5. Long-Acting Injectable ART Considerations: Optimizing Clinical Workflows and Treatment Recommendations for People with HIV

January 2026

Presented by:
Helen Koenig, MD, MPH
Professor of Clinical Medicine, Infectious Diseases
University of Pennsylvania, Perelman School of Medicine
Medical Director, MacGregor Infection Medicine & Travel Clinic
Medical Director, PrEP Program, Philadelphia FIGHT

Learning Objectives: 

1. Discuss dosage and prescribing guidelines for long-acting injectable antiretroviral therapy (ART), including pharmacokinetics, potential side effects, and clinical management plans for patients with HIV.
   

2. Evaluate the criteria for selecting appropriate candidates for long-acting injectable ART, considering factors such as adherence, access, and comorbid conditions. 
   

3. Analyze clinical workflows that can be adapted to incorporate long-acting injectable ART into routine care, including scheduling, patient education, and follow-up procedures.

Activity:
Discuss creative methods to incorporate long-acting injectable ART into clinical workflows by sharing ideas on scheduling, patient education, and follow-up care for patients with HIV within small groups. 

6. Integrating HIV Care, Prevention, and Treatment into Primary Care: Workflow, Billing, and Team-Based Models

February 2026

Presenter TBA 

Learning Objectives: 

1. Describe the key components of a comprehensive HIV care continuum—including screening, prevention (PrEP/PEP), diagnosis, treatment initiation, and long-term management—within the primary care setting.
   

2. Explore the role of interdisciplinary team members (e.g., medical assistants, pharmacists, behavioral health providers) in the delivery of HIV care and prevention services within a primary care setting.
   

3. Identify workflow strategies and clinical decision support tools to routinely screen for HIV and initiate or manage antiretroviral therapy (ART) for newly diagnosed or previously established patients.
   

4. Discuss common billing and coding approaches for HIV-related services, including HIV screening, PrEP management, ART monitoring, and patient education.

Activity:
Analyze a primary care–based case scenario and formulate a collaborative HIV care plan, including clinical decisions and care coordination strategies.

7. Hepatitis B Management Across the HIV Care Continuum

March 2026

Presenter TBA

Learning Objectives: 

1. Describe the prevalence and clinical implications of Hepatitis B (HBV) co-infection in individuals with HIV, including screening guidelines and treatment considerations.
   

2. Explore evidence-based strategies for the management of HBV in people with HIV and discuss the importance of monitoring and follow-up care.
   

3. Discuss best practice approaches for counseling patients with HIV and HBV coinfection and identify strategies to improve access to treatment.
   

4. Describe the role of a multidisciplinary team in managing HIV and HBV coinfection and opportunities to leverage technology to enhance clinical outcomes.

Activity:
Participants will engage in discussions to collaboratively address challenges and strategies for providing comprehensive care and HBV management in patients with HIV.

8. HIV and Cardiovascular Disease: Whole-Person Chronic Disease Care

April 2026

Presenter TBA

Learning Objectives: 

1. Describe the pathophysiological mechanisms linking HIV infection, chronic inflammation, and antiretroviral therapy (ART) with increased cardiovascular disease (CVD) risk in people with HIV (PWH).
   

2. Compare traditional and HIV-specific cardiovascular risk assessment tools (e.g., ASCVD calculator vs. D:A:D risk score), and apply these tools in case-based scenarios to stratify CVD risk in PWH.
   

3. Identify key modifiable risk factors for CVD in PWH and discuss approaches for integrating appropriate screening and management strategies into a clinical care plan.
   

4. Evaluate the impact of specific ART regimens on lipid profiles, insulin sensitivity, and cardiovascular outcomes, and discuss guidelines to adjust treatment plans accordingly in collaboration with HIV care teams.

Activity:
In small groups, formulate a patient-centered CVD prevention and management plan that integrates lifestyle modification, pharmacologic therapy, and HIV-specific considerations. 

9. ART Meets A1C: Precision Medicine for HIV & Diabetes Dual-Diagnosis

May 2026

Presenter TBA

Learning Objectives: 

1. Describe the bidirectional impact of HIV and diabetes on chronic disease progression, treatment outcomes, and the pathophysiologic interplay, including chronic inflammation, insulin resistance, and lipodystrophy.
   

2. Identify common pharmacologic and non-pharmacologic challenges and strategies in the co-management of HIV and diabetes, considering drug interactions, monitoring considerations, and lifestyle interventions.
   

3. Apply current clinical guidelines for managing co-morbid HIV and diabetes while evaluating ART regimens for metabolic impacts and identifying modifications to minimize risks.
   

4. Describe best practices for developing individualized care plans that prioritize whole-person care, adherence, and engagement in care, integrating diabetes management strategies into the HIV care continuum.

Activity:
Participants will engage in poll questions, peer discussions, and interdisciplinary decision-making to apply concepts of HIV and diabetes co-management and whole-person care using a simulated dynamic patient case study.

10. Navigating HIV & Respiratory Diseases: Integrating Diagnosis and Management into the HIV Care Continuum

May 2026

Presenter TBA

Learning Objectives: 

1. Explore the evolving spectrum of respiratory diseases in people with HIV (PWH), including opportunistic infections, seasonal viral pathogens, chronic lung disease, and malignancy.
   

2. Describe diagnostic challenges and imaging findings in PWH with acute and chronic pulmonary symptoms.
   

3. Discuss the role of ART, immune status, and comorbidities (e.g., smoking, COPD, TB exposure) in the pathophysiology of lung disease and infection susceptibility in patients with HIV. 
   

4. Identify evidence-based management and prevention strategies for respiratory diseases in PWH, including the use of antimicrobial prophylaxis, vaccination, inhaled therapies, and screening for chronic lung conditions and malignancy.

Activity:
In three interconnected mini-cases, participants will assess and manage individuals with HIV who present respiratory symptoms during the respiratory infection season. Participants will engage in discussions on differential diagnosis, respond to poll questions, and simulate treatment decisions using best practices.

11. HIV-Related Cutaneous Manifestations and Dermatologic Conditions

June 2026

Presenter TBA

Learning Objectives: 

1. Identify and describe the various cutaneous manifestations associated with HIV, including opportunistic infections and skin-related side effects of antiretroviral therapy.
   

2. Describe the mechanisms by which HIV affects the skin and the immune response, leading to specific dermatologic conditions.
   

3. Discuss appropriate treatment regimens for common dermatological manifestations in people with HIV.

Activity:
Utilize case discussions and visual aids to practice accurately assessing and diagnosing common skin conditions associated with HIV.